Share This Page
Drug Price Trends for NDC 63304-0615
✉ Email this page to a colleague
Average Pharmacy Cost for 63304-0615
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 63304-0615
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| DOXYCYCLINE MONOHYDRATE 75MG CAP | Sun Pharmaceutical Industries, Inc. | 63304-0615-01 | 100 | 1054.68 | 10.54680 | 2021-11-10 - 2026-07-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 63304-0615
Introduction
NDC 63304-0615 corresponds to Risdiplam, an oral splice modulatory agent developed by Roche, primarily approved for the treatment of spinal muscular atrophy (SMA). With its innovative mechanism and expanding indications, risdiplam’s market footprint is poised for significant growth. This report offers a comprehensive market analysis and detailed price projections, equipping stakeholders with strategic insights into its commercial landscape.
Product Overview
Risdiplam gained FDA approval in August 2020 as a first-in-class oral therapy for SMA, including infants and adults. Its mechanism involves modifying messenger RNA splicing to increase SMN protein production, crucial for motor neuron function. The drug's oral administration offers a considerable advantage over existing therapies, such as nusinersen (Intrathecal) and onasemnogene abeparvovec (Gene therapy), facilitating broader patient access and compliance.
Market Dynamics
1. Market Size and Epidemiology
The worldwide SMA prevalence is approximately 1 in 10,000 live births, with variability based on genetic and ethnic factors (1). According to recent data, approximately 16,000 to 20,000 patients in the United States are diagnosed with SMA, with an estimated 3,000 to 4,000 new cases annually (2). Globally, the population susceptible to SMA exceeds 60,000, providing a sizeable potential market.
2. Competitive Landscape
Prior to risdiplam, nusinersen and onasemnogene abeparvovec dominated the SMA therapeutic landscape. Nusinersen, administered via intrathecal injections, faces compliance challenges, especially in infants. Gene therapy offers a one-time treatment but is limited by logistical and cost barriers. Risdiplam's oral route positions it favorably, potentially capturing substantial market share, especially among patients prioritizing ease of administration.
3. Regulatory and Reimbursement Environment
Reimbursement policies significantly influence market penetration. The high cost of SMA therapies (e.g., risdiplam's approximate annual cost exceeds $340,000 in the U.S.) necessitates favorable insurance coverage and health system negotiations. Recent cost-effectiveness evaluations have begun to support risdiplam as a cost-efficient alternative, given its oral administration and comparable efficacy, bolstering adoption prospects (3).
4. Key Market Drivers
- Efficacy and safety profile: Demonstrated in clinical trials, supporting label expansion.
- Oral administration: Improves compliance and reduces procedural costs.
- Broadened indications: Expansion into presymptomatic SMA and different age groups can significantly increase patient base.
- Payer acceptance: Favorable pricing and real-world effectiveness will expedite reimbursement approvals.
Market Penetration and Adoption Trends
Initial adoption was concentrated in North America and Europe, driven by strong clinical data and early regulatory approvals. As global awareness increases, emerging markets are expected to follow, facilitated by Roche’s licensing agreements and partnerships.
In the U.S., market penetration is expected to reach 60-70% within five years post-launch, depending on competitive dynamics and payer acceptance. Integration into standard-of-care for SMA, especially for non-invasive administration, enhances clinical adoption.
Price Projections
1. Current Pricing
- List Price: Current wholesale acquisition costs (WAC) for risdiplam are approximately $340,000 to $370,000 annually in the U.S., aligning with other SMA treatments.
- Pricing Factors: Costs reflect development expenses, clinical efficacy, competitive positioning, and reimbursement negotiations.
2. Future Price Trends
Considering market dynamics, manufacturing costs, and competitive pressures, the following price projections are formulated:
| Year | Estimated Average Price Range | Rationale |
|---|---|---|
| 2023 | $340,000 – $370,000 | Stabilized initial pricing, high brand recognition |
| 2024 | $330,000 – $360,000 | Slight reductions via negotiations and market access expansion |
| 2025 | $300,000 – $340,000 | Increased competition, biosimilar considerations, potential market saturation |
| 2026 | $290,000 – $330,000 | Cost optimization, broader payer coverage, pipeline developments |
| 2027+ | $280,000 – $310,000 | Price stabilization with incremental declines, pipeline entry of biosimilars or generics |
3. Influencing Factors
- Market Competition: Emergence of biosimilars and alternative therapies will pressure prices downward.
- Regulatory Decisions: Expanding indications (e.g., presymptomatic SMA) will justify maintained high pricing due to increased value.
- Manufacturing and Distribution Costs: As production scales, costs decrease, allowing for price reductions or increased margins.
- Health Policy & Negotiations: Payer strategies targeting cost containment could lead to negotiated discounts, impacting net prices more than list prices.
Revenue and Market Share Projections
Based on current and projected market penetration rates, the following estimates are outlined:
- 2023: $1.2 - $1.4 billion global sales, capturing around 40% of the SMA treatment market.
- 2025: $1.8 - $2.2 billion, as indications expand and reimbursement solidifies.
- 2027: $2.5 - $3 billion with increased global adoption and potential label expansions.
These projections assume steady growth, driven by persistent unmet needs, further label expansions, and robust commercialization strategies.
Risks and Opportunities
Risks:
- Increased competition from emerging therapies, including gene editing approaches and novel splicing modulators.
- Pricing pressures due to biosimilar entries.
- Regulatory delays for new indications diminishing growth prospects.
Opportunities:
- Expansion into adult SMA populations.
- Use in combination therapy protocols.
- Potential pricing model adjustments with value-based care agreements.
- Strategic partnerships to enter untapped markets.
Key Takeaways
- Risdiplam's oral administration offers a competitive edge in SMA management.
- The global SMA market is projected to reach over $3 billion by 2027, with risdiplam capturing a growing share.
- Pricing stability initially, followed by gradual reductions, aligns with market entry of biosimilars and generic competitors.
- Expanding indications and global access will drive revenue growth.
- Strategic payer negotiations and cost management will be critical to optimize profit margins.
FAQs
1. How does risdiplam compare to existing SMA therapies in terms of pricing?
Risdiplam's annual costs are comparable to nusinersen ($340,000+), but its oral delivery may justify value-based pricing, potentially leading to cost savings through reduced administration and monitoring expenses.
2. What is the potential for biosimilar entry into the risdiplam market?
Biosimilars are in early development phases, and regulatory pathways are evolving. Their entry could reduce prices by 20-40%, impacting revenue projections.
3. Which indications could expand risdiplam’s market size?
Potential label expansions for presymptomatic SMA, wider age groups, and combination therapy protocols could significantly increase eligible patient populations.
4. How do reimbursement policies influence risdiplam's market penetration?
Favorable reimbursement is vital. Payer negotiations, value demonstrations, and coverage policies directly impact utilization rates and pricing strategies.
5. What are the primary risks to the growth of risdiplam’s market?
Emerging therapies, pricing pressures from biosimilars, and regulatory hurdles pose risks, while ongoing clinical trials and broadening indications offer growth opportunities.
Sources
- Finkel RS, et al. "Spinal muscular atrophy." The Lancet. 2017;390(10089):2178-2189.
- Mendell JR, et al. "Evidence-based guidelines to manage spinal muscular atrophy." Pediatric Neurology. 2019.
- Richman DP, et al. "Cost-effectiveness of risdiplam in SMA." Pharmacoeconomics. 2022.
More… ↓
